Central benzodiazepine receptors in human brain: estimation of regional Bmax and KD values with positron emission tomography.

Studies of central benzodiazepine receptors in the human brain in vivo are now possible using positron emission tomography (PET) and [11C]flumazenil. With the aim of measuring Bmax and Kd in brain regions, we used a two-injection [11C]flumazenil (at high and low specific radioactivity, respectively) pseudo-equilibrium paradigm to evaluate, in seven unmedicated healthy volunteers, the relative merits of three 'reference' structures (pons, hemispheric white matter and corpus callosum) in which the free radioligand concentration in brain tissue was estimated 15-40 min after i.v. injection of the radioligand. By means of high-resolution PET, the Bmax and Kd were calculated for each subject in 18 gray matter structures, based on a two-point Scatchard plot. We found that the use of the corpus callosum as reference often resulted in spurious Bmax and Kd values. The pons was the best reference structure because it provided satisfactory Bmax values (closest to in vitro data) and most consistent Kd values, and was the region easiest to sample on PET images. The pattern of regional Bmax was consistent with that expected from in vitro studies, with values highest in the cerebral cortex, intermediate in the cerebellum, and lowest in the striatum and the thalamus. The Kd values were uniform among regions and were consistent with earlier in vitro and in vivo data. This work documents the feasibility of estimating Bmax and Kd of central benzodiazepine receptors in multiple brain regions for clinical research.

[1]  D Comar,et al.  Synthesis of ethyl 8-fluoro-5,6-dihydro-5-[11C]methyl-6-oxo-4H-imidazo [1,5-a] [1,4]benzodiazepine-3-carboxylate (RO 15.1788-11C): a specific radioligand for the in vivo study of central benzodiazepine receptors by positron emission tomography. , 1984, The International journal of applied radiation and isotopes.

[2]  G. Sedvall,et al.  Temperature Dependence of [3H]Ro 15–1788 Binding to Benzodiazepine Receptors in Human Postmortem Brain Homogenates , 1990, Journal of neurochemistry.

[3]  M. Kuhar,et al.  Benzodiazepine receptor binding in vivo with [3H]-Ro 15-1788. , 1985, Life sciences.

[4]  S. Stone-Elander,et al.  11C-labelling of Ro 15-1788 in two different positions, and also 11C-labelling of its main metabolite Ro 15-3890, for PET studies of benzodiazepine receptors. , 1988, International journal of radiation applications and instrumentation. Part A, Applied radiation and isotopes.

[5]  E. Brouillet,et al.  Quantitative evaluation of benzodiazepine receptors in live Papio papio baboons using positron emission tomography. , 1990, Molecular pharmacology.

[6]  G. Sedvall,et al.  IN-VIVO DEMONSTRATION OF REDUCED BENZODIAZEPINE RECEPTOR BINDING IN HUMAN EPILEPTIC FOCI , 1988, The Lancet.

[7]  I. Martin,et al.  Kinetics of [3H]Ro 15–1788 Binding to Membrane‐Bound Rat Brain Benzodiazepine Receptors , 1984, Journal of neurochemistry.

[8]  H. Mohler,et al.  Benzodiazepine receptor: demonstration in the central nervous system , 1977, Science.

[9]  D Comar,et al.  Kinetics and displacement of [11C]RO 15-1788, a benzodiazepine antagonist, studied in human brain in vivo by positron tomography. , 1985, European journal of pharmacology.

[10]  I. Appollonio,et al.  Benzodiazepine receptors and diazepam‐binding inhibitor in human cerebral tumors , 1989, Annals of neurology.

[11]  Christer Halldin,et al.  Saturation analysis of specific 11C Ro 15‐1788 binding to the human neocortex using positron emission tomography , 1989 .

[12]  G. Blomqvist,et al.  Cortical Benzodiazepine Receptor Binding in Patients with Generalized and Partial Epilepsy , 1990, Epilepsia.

[13]  S. Snyder,et al.  Huntington's disease , 1987, Neurology.

[14]  C. Braestrup,et al.  Benzodiazepine receptors in rat brain , 1977, Nature.

[15]  S. Stone-Elander,et al.  D2 dopamine receptors in neuroleptic-naive schizophrenic patients. A positron emission tomography study with [11C]raclopride. , 1990, Archives of general psychiatry.

[16]  Edgar M. Housepian Atlas d'anatomie stereotaxique du telencephale. , 1968 .

[17]  J. Richards,et al.  Agonist and antagonist benzodiazepine receptor interaction in vitro , 1981, Nature.

[18]  J. Rossier,et al.  In vivo binding of (3H)Ro 15-1788 in mice: comparison with the in vivo binding of (3H)flunitrazepam. , 1988, Life sciences.

[19]  C. Swahn,et al.  Metabolism of the benzodiazepine antagonist 11C‐Ro 15‐1788 after intravenous administration in man , 1989 .

[20]  R. Naquet,et al.  Central type benzodiazepine binding sites: A positron emission tomography study in the baboon's brain , 1984, Neuroscience Letters.

[21]  O. Inoue,et al.  Alterations in biodistribution of [3H]Ro 15-1788 in mice by acute stress: possible changes in in vivo binding availability of brain benzodiazepine receptor. , 1985, International journal of nuclear medicine and biology.

[22]  O. Inoue,et al.  Visualization of specific binding sites of benzodiazepine in human brain. , 1986, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[23]  K. Jellinger,et al.  Comparison of benzodiazepine receptor binding in membranes from human or rat brain , 1985, Neuropharmacology.

[24]  M. Raichle,et al.  A Stereotactic Method of Anatomical Localization for Positron Emission Tomography , 1985, Journal of computer assisted tomography.

[25]  J. Baron,et al.  A comparison of methods for the separation of [11C]Ro 15-1788 (flumazenil) from its metabolites in the blood of rabbits, baboons and humans. , 1991, International journal of radiation applications and instrumentation. Part A, Applied radiation and isotopes.

[26]  J. Baron,et al.  Regional Specific Binding of [11C]RO 15 1788 to Central Type Benzodiazepine Receptors in Human Brain: Quantitative Evaluation by PET , 1988, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[27]  M. Iyo,et al.  Quantitative in vivo analysis of benzodiazepine binding sites in the human brain using positron emission tomography , 1991, Neuropharmacology.